A phage-encoded anti-CRISPR enables complete evasion of type VI-A CRISPR-Cas immunity

Citations Over TimeTop 10% of 2020 papers

Abstract

The CRISPR RNA (crRNA)-guided nuclease Cas13 recognizes complementary viral transcripts to trigger the degradation of both host and viral RNA during the type VI CRISPR-Cas antiviral response. However, how viruses can counteract this immunity is not known. We describe a listeriaphage (ϕLS46) encoding an anti-CRISPR protein (AcrVIA1) that inactivates the type VI-A CRISPR system of Listeria seeligeri Using genetics, biochemistry, and structural biology, we found that AcrVIA1 interacts with the guide-exposed face of Cas13a, preventing access to the target RNA and the conformational changes required for nuclease activation. Unlike inhibitors of DNA-cleaving Cas nucleases, which cause limited immunosuppression and require multiple infections to bypass CRISPR defenses, a single dose of AcrVIA1 delivered by an individual virion completely dismantles type VI-A CRISPR-mediated immunity.

Related Papers

• → The advancements, challenges, and future implications of the CRISPR/Cas9 system in swine research(2021)23 cited
• → Using CRISPR/Cas9 Technology for Manipulating Cell Death Regulators(2016)25 cited
• → The emerging role of CRISPR-Cas9 in molecular oncology(2017)1 cited
• → Brief Introduction to CRISPR Cas9(2022)
• → ИСПОЛЬЗОВAНИЕ ПОТЕНЦИAЛA СОЦИAЛЬНЫХ ПAРТНЕРОВ В ПОДГОТОВКЕ БУДУЩИХ ПЕДAГОГОВ(2024)